Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01516879
Registration number
NCT01516879
Ethics application status
Date submitted
18/01/2012
Date registered
25/01/2012
Date last updated
22/07/2022
Titles & IDs
Public title
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Query!
Scientific title
A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects
Query!
Secondary ID [1]
0
0
20110109
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DESCARTES
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Evolocumab
Treatment: Other - Placebo
Treatment: Drugs - Atorvastatin
Treatment: Drugs - Ezetimibe
Other interventions - Diet Only
Experimental: Evolocumab - Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
Placebo comparator: Placebo - Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
Treatment: Other: Evolocumab
Administered by subcutaneous injection once a month
Treatment: Other: Placebo
Administered by subcutaneous injection once a month
Treatment: Drugs: Atorvastatin
Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
Treatment: Drugs: Ezetimibe
Background lipid lowering therapy: ezetimibe 10 mg orally once a day
Other interventions: Diet Only
Diet only, no lipid lowering background drug given
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Intervention code [3]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percent Change From Baseline in LDL-C at Week 52
Query!
Assessment method [1]
0
0
Cholesterol was measured by means of ultracentrifugation.
Query!
Timepoint [1]
0
0
Baseline and Week 52
Query!
Secondary outcome [1]
0
0
Change From Baseline in LDL-C at Week 52
Query!
Assessment method [1]
0
0
Cholesterol was measured by means of ultracentrifugation.
Query!
Timepoint [1]
0
0
Baseline and Week 52
Query!
Secondary outcome [2]
0
0
Percentage of Participants With an LDL-C Response at Week 52
Query!
Assessment method [2]
0
0
An LDL-C response is defined as LDL-C level \< 70 mg/dL (1.8 mmol/L) at Week 52.
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline in LDL-C at Week 12
Query!
Assessment method [3]
0
0
Cholesterol was measured by means of ultracentrifugation.
Query!
Timepoint [3]
0
0
Baseline and Week 12
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline in Total Cholesterol at Week 12
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline and Week 12
Query!
Secondary outcome [5]
0
0
Percent Change From Baseline in Total Cholesterol at Week 52
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline and Week 52
Query!
Secondary outcome [6]
0
0
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline and Week 52
Query!
Secondary outcome [7]
0
0
Percent Change From Baseline in Apolipoprotein B at Week 52
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline and Week 52
Query!
Secondary outcome [8]
0
0
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline and Week 52
Query!
Secondary outcome [9]
0
0
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline and Week 52
Query!
Secondary outcome [10]
0
0
Percent Change From Baseline in Lipoprotein(a) at Week 52
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Baseline and Week 52
Query!
Secondary outcome [11]
0
0
Percent Change From Baseline in Triglycerides at Week 52
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Baseline and Week 52
Query!
Secondary outcome [12]
0
0
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Baseline and Week 52
Query!
Secondary outcome [13]
0
0
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52
Query!
Assessment method [13]
0
0
Cholesterol was measured by means of ultracentrifugation.
Query!
Timepoint [13]
0
0
Baseline and Week 52
Query!
Secondary outcome [14]
0
0
Percent Change From Week 12 to Week 52 in LDL-C
Query!
Assessment method [14]
0
0
Cholesterol was measured by means of ultracentrifugation.
Query!
Timepoint [14]
0
0
Week 12 and Week 52
Query!
Eligibility
Key inclusion criteria
* Subject has provided informed consent.
* Fasting LDL-C = 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:
* < 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk equivalent
* < 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent
* OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO QD and ezetimibe 10 mg PO QD
* Fasting triglycerides = 400 mg/dL
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular ejection fraction < 30%
* Uncontrolled cardiac arrhythmia
* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization, type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes
* Uncontrolled hypertension
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/01/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
905
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Research Site - Maroubra
Query!
Recruitment hospital [3]
0
0
Research Site - Carina Heights
Query!
Recruitment hospital [4]
0
0
Research Site - Milton
Query!
Recruitment hospital [5]
0
0
Research Site - Fitzroy
Query!
Recruitment hospital [6]
0
0
Research Site - Perth
Query!
Recruitment postcode(s) [1]
0
0
2015 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [3]
0
0
4152 - Carina Heights
Query!
Recruitment postcode(s) [4]
0
0
4064 - Milton
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [6]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maine
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Mississippi
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nevada
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New York
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Carolina
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Dakota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oklahoma
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
South Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Feldkirch
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Innsbruck
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Salzburg
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Wels
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Anthée
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Bruxelles
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Gent
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Gozee
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Ham
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Oostende
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
British Columbia
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Newfoundland and Labrador
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Brno
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Chomutov
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Hradec Kralove
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Pardubice
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Plzen
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Praha 2
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Praha 4
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Praha 5
Query!
Country [48]
0
0
Czechia
Query!
State/province [48]
0
0
Slany
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Aalborg
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Ballerup
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Vejle
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Baja
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Budapest
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Komarom
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Pecs
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Szeged
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Zalaegerszeg
Query!
Country [58]
0
0
South Africa
Query!
State/province [58]
0
0
Gauteng
Query!
Country [59]
0
0
South Africa
Query!
State/province [59]
0
0
KwaZulu-Natal
Query!
Country [60]
0
0
South Africa
Query!
State/province [60]
0
0
Western Cape
Query!
Country [61]
0
0
South Africa
Query!
State/province [61]
0
0
Bloemfontein
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01516879
Query!
Trial related presentations / publications
Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, Elliott M, Davis M, Somaratne R, Preiss D. Effect of Evolocumab on Lipoprotein Particles. Am J Cardiol. 2018 Feb 1;121(3):308-314. doi: 10.1016/j.amjcard.2017.10.028. Epub 2017 Nov 8. Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 Jan;19(1):98-107. doi: 10.1111/dom.12788. Epub 2016 Oct 14. Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, Roth E. Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study. Circ Res. 2015 Sep 25;117(8):731-41. doi: 10.1161/CIRCRESAHA.115.307071. Epub 2015 Jul 30. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29. Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16. Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7. Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31. Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2. Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16. Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug;16(4):538-543. doi: 10.1016/j.jacl.2022.05.069. Epub 2022 Jun 6.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01516879
Download to PDF